Canavan Disease (CD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Canavan Disease (CD) Market Outlook Thelansis’s “Canavan Disease (CD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Canavan Disease (CD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Canavan Disease (CD) Overview Canavan disease (CD) is a genetic degenerative brain disease caused by a lack of the enzyme aspartoacylase (ASPA). N-acetylaspartic acid builds up in the brain and other body parts when ASPA activity is lost. CD is diagnosed by detecting elevated NAA in urine, blood, or the brain by proton MR spectroscopy and ASPA mutation analysis. Insufficient myelination and progressive spongy degeneration of the brain’...